Triple attack on prostate cancer: drug, surgery, and radiation aim to stop spread

NCT ID NCT07490210

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding surgery and targeted radiation to a new hormone-blocking drug (rezvilutamide) can help men whose prostate cancer has spread to a few spots (oligometastatic). 300 men will be split into three groups: one gets the drug alone, one gets drug plus surgery, and one gets drug plus surgery plus radiation. The goal is to see which approach best delays cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rezvilutamide (a hormone-blocking drug) plus androgen deprivation therapy (ADT)
What this could lead to
If successful, this combination approach could offer a way to delay cancer progression and improve survival for men with prostate cancer that has spread to a few spots.
What could go wrong
This is an early Phase 2 trial, so results are not yet proven. The added treatments (surgery and radiation) carry risks like side effects from surgery or radiation, and the drug may cause fatigue, hot flashes, or other hormone-related issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.